Results 81 to 90 of about 15,755 (201)

Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs

European Journal of Haematology, EarlyView.
ABSTRACT Acute lymphoblastic leukaemia (ALL) in older adults represents a growing clinical challenge, driven by an ageing population, adverse disease biology, and reduced tolerance to intensive chemotherapy. Although pediatric‐inspired regimens have improved outcomes in younger adults with Philadelphia chromosome (Ph)‐negative ALL, survival in older ...
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Santino Caserta, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Marco Fiorillo, Nicola Amodio, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Myeloma Treatment on SÄS – Does it conform to good national standard? [PDF]

, 2017
Myeloma Treatment on SÄS – Does it conform to good national standard? Stefan Carslöv Supervisor: Ulf-Henrik Mellqvist Department of Medicine, Södra Älvsborg Hospital, Borås, Sweden Introduction Myeloma has an incidence of approximately 600 patient per ...
Carslöv, Stefan
core  

Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab‐Based Regimens

European Journal of Haematology, EarlyView.
ABSTRACT Gain/amplification of chromosome arm 1q (+1q) is among the most frequent cytogenetic abnormalities (CAs) in multiple myeloma (MM), and a recognized marker of poor prognosis, now integrated into modern risk stratification systems. The advent of anti‐CD38 monoclonal antibodies, particularly daratumumab, has significantly improved outcomes ...
Emiliano Barbieri, Laura Arletti, Micol Quaresima, Elena Rivolti, Luca Braglia, Cecilia Fabiano, Adriana Maria Rita Alfano, Monia Rinaldini, Veronica Bizzarri, Chiara Cattani, Maria Marinelli, Barbara Gamberi   +11 more
wiley   +1 more source

Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumab

Haematologica
Daratumumab is an anti-CD38 monoclonal antibody that has shown clinical benefit in both relapsed/refractory as well as newly diagnosed multiple myeloma (MM).
Guido Lancman, Dahniel Sastow, Minira Aslanova, Erin Moshier, Hearn Jay Cho, Sundar Jagannath, Samir Parekh, Shambavi Richard, Joshua Richter, Cesar Rodriguez, Adriana Rossi, Larysa Sanchez, Santiago Thibaud, Ajai Chari   +13 more
doaj   +1 more source

Unusual Cutaneous and Lymphatic Findings in an Adult Patient

JEADV Clinical Practice, EarlyView.
Sarah Preis, Mara Hubbuch, Susanne Annette Steimle‐Grauer, Tilo Biedermann, Oana‐Diana Persa   +4 more
wiley   +1 more source

Mitochondrial transfer in acute myeloid leukaemia and multiple myeloma: Mechanisms, consequences and potential therapeutic opportunities

The FEBS Journal, EarlyView.
Mitochondria can be transferred from bone marrow cells to cancer cells in acute myeloid leukaemia and multiple myeloma, boosting tumour energy production, growth, and drug resistance. This review highlights key transfer mechanisms and shows how targeting mitochondrial movement and dynamics may offer new therapeutic strategies to limit cancer ...
Ebubechukwu Nwarunma, Mark T. S. Williams   +1 more
wiley   +1 more source

Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells

OncoImmunology, 2019
Daratumumab is an anti-CD38 fully human IgG1 mAb approved for multiple myeloma treatment. One of the proposed mechanisms of action is the induction of antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells.
Maria C. Ochoa, Elisabeth Perez-Ruiz, Luna Minute, Carmen Oñate, Guiomar Perez, Inmaculada Rodriguez, Aintzane Zabaleta, Diego Alignani, Myriam Fernandez-Sendin, Ascension Lopez, Aura Muntasell, Miguel F. Sanmamed, Bruno Paiva, Miguel Lopez-Botet, Pedro Berraondo, Ignacio Melero   +15 more
doaj   +1 more source

Resultados en salud en el tratamiento del mieloma múltiple [PDF]

, 2019
Introducción: El mieloma múltiple es una neoplasia caracterizada por la proliferación incontrolada de células plasmáticas. Es necesario realizar un análisis retrospectivo para evaluar la efectividad de los tratamientos administrados ...
Aguado Paredes, Alicia
core  

Clinical implications of imlifidase interference in antibody screening and transfusion management

Transfusion, EarlyView.
Abstract Background Imlifidase has received conditional approval from the EMA for desensitizing deceased donor kidney transplant recipients. It works by cleaving IgG into F(ab′)2 and Fc fragments, thereby reducing the risk of antibody‐mediated rejection. However, its impact on diagnostic assays remains understudied. Case Report We present the case of a
Zgjim Osmani, Aiko P. J. de Vries, Arjan Albersen   +2 more
wiley   +1 more source

B09 | DARATUMUMAB MONOTHERAPY VERSUS ACTIVE MONITORING IN PATIENTS WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA: "AQUILA" OUTCOMES BASED ON MAYO 2018/IMWG 2020 RISK STRATIFICATION, IMWG 2020 PLUS CYTOGENETIC CRITERIA, AND AGE

Haematologica
Introduction. Patients with high-risk smoldering multiple myeloma (SMM) may benefit from early treatment. With SMM risk stratification advancement, post hoc analysis of the AQUILA study using IMWG 2020 (“20/2/20”) and other risk models was conducted to ...
F. Schjesvold, P.M. Voorhees, M.A. Dimopoulos, Y.C. Cohen, V. Hungria, I. Sandhu, J. Lindsay, R.I. Baker, K. Suzuki, H. Kosugi, M-D. Levin, M. Beksac, K. Stockerl-Goldstein, H. Magen, A. Oriol, G. Mikala, G. Garate, K. Theunissen, I. Spicka, A.K. Mylin, S. Hallam, S. Bringhen, K. Uttervall, B. Pula, A.M. Khan, E. Medvedova, J.C. Ye, A.J. Cowan, Ph. Moreau, M-V. Mateos, H. Goldschmidt, D. Vieyra, A. Raval, L. Sha, L. Li, E. Rousseau, R.M. Dennis, R.L. Carson, S.V. Rajkumar   +38 more
doaj   +1 more source